Welcome to our dedicated page for TRANSLATE BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TRANSLATE BIO stock.
Telesis Bio Inc. (TBIO) generates news centered on automated DNA and mRNA synthesis technologies, strategic collaborations and corporate developments. The company describes itself as a public company based in San Diego, California, focused on enabling scientists to produce high-fidelity DNA and mRNA directly in their own laboratories using its Gibson SOLA Enzymatic Synthesis platform and BioXp benchtop systems.
News coverage for Telesis Bio often highlights progress and adoption of the Gibson SOLA™ platform, which the company presents as a non-toxic, high-fidelity and scalable enzymatic DNA and mRNA synthesis technology. Announcements have included licensing agreements, such as the deployment of Gibson SOLA at Regeneron Pharmaceuticals’ R&D core facilities, and collaborations that integrate Gibson SOLA with third-party automation platforms to support on-premises biofoundry capabilities.
Investors and researchers following TBIO can expect updates on partnerships and collaborations, including the company’s strategic research collaboration and license agreement with Pfizer related to enzymatic DNA synthesis for potential mRNA-based vaccines and other biopharma products. Additional news may cover agreements with automation and life sciences companies to co-develop and market integrated solutions for high-throughput nucleic acid synthesis.
Corporate and capital markets developments also appear in Telesis Bio’s news flow. Examples include restructuring activities, strategic focus on Gibson SOLA and BioXp mRNA solutions, reverse stock split actions, and the company’s decision to voluntarily delist from The Nasdaq Global Select Market and pursue quotation on over-the-counter markets. For anyone tracking TBIO, the news stream provides context on how the company is positioning its synthesis platforms, managing its cost structure and engaging with partners in synthetic biology and drug discovery workflows.
Translate Bio and Sanofi Pasteur have expanded their collaboration to develop mRNA vaccines for infectious diseases, building on a 2018 agreement. Translate Bio will receive $425 million upfront, comprising $300 million in cash and a $125 million stock investment, plus potential milestone payments up to $1.9 billion. Sanofi gains exclusive rights to develop and commercialize these vaccines. The partnership combines Translate Bio's mRNA technology with Sanofi's vaccine expertise, aiming for a first-in-human clinical trial for a COVID-19 vaccine by late 2020 and further vaccine programs against influenza and other pathogens.
Translate Bio (Nasdaq: TBIO), a clinical-stage mRNA therapeutics company, has announced that CEO Ronald Renaud will participate in a fireside chat at the Bank of America Securities Virtual 2020 Health Care Conference on May 14, 2020, at 9:00 a.m. ET. This session will be available via live webcast on the Company's website, with a replay accessible for 30 days after the event.
Translate Bio is notably focused on developing transformative medicines for diseases linked to protein dysfunction, including a lead program targeting cystic fibrosis currently in a Phase 1/2 clinical trial.
Translate Bio (Nasdaq: TBIO) announced financial results for Q1 2020, reporting a net loss of $14.3 million compared to $33.2 million in Q1 2019. The collaboration with Sanofi Pasteur to develop an mRNA COVID-19 vaccine is ongoing, with multiple candidates in evaluation for clinical trials set to start in Q4 2020. The company ended the quarter with $155.1 million in cash and expects funding to last into Q3 2021. Collaboration revenue rose to $4.7 million driven by increased activities. Operating expenses decreased to $19.4 million, reflecting ongoing vaccine program advancements.